D. Rishipathak

Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade

E. Newell, Oliver A. Zill, S. Mariathasan, 2022, Journal for ImmunoTherapy of Cancer.

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2020, Nature Medicine.

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2020, Nature Medicine.

Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2021, Nature medicine.

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

P. Hegde, Z. Modrušan, James Ziai, 2022, Cell reports. Medicine.

Differential increase in the expression of heat shock protein family members during sleep deprivation and during sleep

H. Heller, A. Apte-Deshpande, T. Kilduff, 2003, Neuroscience.

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

F. Hodi, Y. Bang, M. Sznol, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.

E. Skinner, B. Inman, S. Mariathasan, 2023, European urology oncology.

658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)

Jun Zhu, M. Galsky, E. Kikuchi, 2021, Annals of Oncology.